PERSIST-1 phase III study of pacritinib versus BAT in PMF, PPV-MF, or PET-MF
ASCO 2015: Ruben Mesa, MD, FACP discusses the results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF).
Recent Video
Most Popular
Specialties :                    Search :


MPNUniversity.tv is a member of the Oncology.TV family of oncology medical education websites. MPNUniversity.tv offers specialists, primary care physicians, and other healthcare professionals the timeliest comprehensive and relevant clinical information to improve patient care. We provide medical education (both free CE and non CE, including interactive case based presentations), news and information about Myeloproliferative Neoplasms (MPNs).